NDAINHALATIONSOLUTION
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
BROVANA (arformoterol tartrate) by Dr. Reddy's Laboratories is arformoterol, the (r,r)-enantiomer of formoterol, is a selective long-acting beta 2 - adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (s,s) and (r,r)-enantiomers). Approved for acute deteriorations of chronic obstructive pulmonary disease, asthma, acute deteriorations of chronic obstructive pulmonary disease [see ] and 2 more indications. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BROVANA is an inhaled solution containing arformoterol tartrate, the active (R,R)-enantiomer of formoterol with two-fold greater potency than racemic formoterol. It is a long-acting beta-2 adrenergic receptor agonist (LABA) indicated for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including acute deteriorations. The drug works by stimulating intracellular adenyl cyclase, increasing cyclic AMP to relax bronchial smooth muscle and inhibit release of inflammatory mediators from mast cells.
$0.394MPart D
LOE ApproachingDeclining
BROVANA is in declining phase with modest Medicare utilization; brand team likely shifting focus to line extensions or preparing for generic competition.
Mechanism of Action
Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta 2 - adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent…
Indications (4)
Worked on BROVANA at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.